Small dense low-density lipoprotein-lowering agents

References

Adams, S.P., Sekhon, S.S., Tsang, M. and Wright, J.M. (2018). Fluvastatin for lowering lipids. Cochrane. Database. Syst. Rev. 3: CD012282. DOI: https://doi.org/10.1002/14651858.CD012282.pub2.Search in Google Scholar PubMed PubMed Central

Ahren, B. and Foley, J.E. (2016). Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on α and β cell function and lipid metabolism. Diabetologia 59: 907–917, DOI: https://doi.org/10.1007/s00125-016-3899-2.Search in Google Scholar PubMed

Ai, M., Otokozawa, S., Asztalos, B.F., Ito, Y., Nakajima, K., White, C.C., Cupples, L.A., Wilson, P.W. and Schaefer, E.J. (2010). Small dense LDL cholesterol and coronary heart disease: results from the Framingham offspring study. Clin. Chem. 56: 967–976, DOI: https://doi.org/10.1373/clinchem.2009.137489.Search in Google Scholar PubMed PubMed Central

Ajith, T.A. and Jayakumar, T.G. (2019). Omega-3 fatty acids in coronary heart disease: recent updates and future perspectives. Clin. Exp. Pharmacol. Physiol. 46: 11–18, DOI: https://doi.org/10.1111/1440-1681.13034.Search in Google Scholar PubMed

Akash, M.S.H., Rehman, K. and Liaqat, A. (2018). Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J. Cell. Biochem. 119: 105–110, DOI: https://doi.org/10.1002/jcb.26174.Search in Google Scholar PubMed

Alagona, P.Jr. and Ahmad, T.A. (2015). Cardiovascular disease risk assessment and prevention: current guidelines and limitations. Med. Clin. North. Am. 99: 711–731, DOI: https://doi.org/10.1016/j.mcna.2015.02.003.Search in Google Scholar PubMed

Allaire, J., Couture, P., Leclerc, M., Charest, A., Marin, J., Lepine, M.C., Talbot, D., Tchernof, A. and Lamarche, B. (2016). A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing EPA to DHA (ComparED) study. Am. J. Clin. Nutr. 104: 280–287, DOI: https://doi.org/10.3945/ajcn.116.131896.Search in Google Scholar PubMed

Allaire, J., Vors, C., Couture, P. and Lamarche, B. (2017). LDL particle number and size and cardiovascular risk: anything new under the sun? Curr. Opin. Lipidol. 28: 261–266, DOI: https://doi.org/10.1097/MOL.0000000000000419.Search in Google Scholar PubMed

Allaire, J., Vors, C., Tremblay, A.J., Marin, J., Charest, A., Tchernof, A., Couture, P. and Lamarche, B. (2018). High-dose DHA has more profound effects on LDL-related features than high-dose EPA: the compared study. J. Clin. Endocrinol. Metab. 103: 2909–2917, DOI: https://doi.org/10.1210/jc.2017-02745.Search in Google Scholar PubMed

Altomonte, J., Cong, L., Harbaran, S., Richter, A., Xu, J., Meseck, M. and Dong, H.H. (2004). Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J. Clin. Invest. 114: 1493–1503, DOI: https://doi.org/10.1172/JCI19992.Search in Google Scholar PubMed PubMed Central

Ambring, A., Friberg, P., Axelsen, M., Laffrenzen, M., Taskinen, M.R., Basu, S. and Johansson, M. (2004). Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. Clin. Sci. (Lond.) 106: 519–525, DOI: https://doi.org/10.1042/CS20030315.Search in Google Scholar

Anber, V., Griffin, B.A., McConnell, M., Packard, C.J. and Shepherd, J. (1996). Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124: 261–271, DOI: https://doi.org/10.1016/0021-9150(96)05842-x.Search in Google Scholar

Andersson, P.E. and Lithell, H. (1996). Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. relationship to changes in skeletal muscle blood flow. Am. J. Hypertens. 9: 323–333, DOI: https://doi.org/10.1016/0895-7061(95)00396-7.Search in Google Scholar

Anholm, C., Kumarathurai, P., Pedersen, L.R., Samkani, A., Walzem, R.L., Nielsen, O.W., Kristiansen, O.P., Fenger, M., Madsbad, S., Sajadieh, A., et al. (2019). Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial. Atherosclerosis 288: 60–66, https://doi.org/10.1016/j.atherosclerosis.2019.07.007.10.1016/j.atherosclerosis.2019.07.007Search in Google Scholar

Arai, H., Kokubo, Y., Watanabe, M., Sawamura, T., Ito, Y., Minagawa, A., Okamura, T. and Miyamato, Y. (2013). Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J. Atheroscler. Thromb. 20: 195–203, DOI: https://doi.org/10.5551/jat.14936.Search in Google Scholar

Ariel, D., Kim, S.H., Abbasi, F., Lamendola, C.A., Liu, A. and Reaven, G.M. (2014). Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutr. Metab. Cardiovasc. Dis. 24: 1317–1322, DOI: https://doi.org/10.1016/j.numecd.2014.06.010.Search in Google Scholar

Backes, J.M. and Gibson, CA. (2005). Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Ann. Pharmacother. 39: 523–526, DOI: https://doi.org/10.1345/aph.1E322.Search in Google Scholar

Bahadir, M.A., Oguz, A., Uzunlulu, M. and Bahadir, O. (2009). Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J. Atheroscler. Thromb. 16: 684–690, DOI: https://doi.org/10.5551/jat.1123.Search in Google Scholar

Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., Keech, A., Simes, J., et al. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681, DOI: https://doi.org/10.1016/S0140-6736(10)61350-5.Search in Google Scholar

Bando, Y., Tohyama, H., Aoki, K., Kanehara, H., Hisada, A., Okafuji, K. and Toya, D. (2016). Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus. J. Clin. Transl. Endocrinol. 6: 1–7, DOI: https://doi.org/10.1016/j.jcte.2016.06.001.Search in Google Scholar PubMed PubMed Central

Bavirti, S., Ghanaat, F. and Tayek, J.A. (2003). Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control. Endocr. Pract. 9: 487–493, DOI: https://doi.org/10.4158/EP.9.6.487.Search in Google Scholar PubMed

Berneis, K., Rizzo, M., Stettler, C., Chappuis, B., Braun, M., Diem, P. and Christ, E.R. (2008). Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert. Opin. Pharmacother. 9: 343–349, DOI: https://doi.org/10.1517/14656566.9.3.343.Search in Google Scholar PubMed

Berneis, K., Rizzo, M., Berthold, H.K., Spinas, G.A., Krone, W. and Gouni-Berthold, I. (2010). Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J. 31: 1633–1639, DOI: https://doi.org/10.1093/eurheartj/ehq181.Search in Google Scholar PubMed

Bezafibrate, I.P.B.J.C. (2000). Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102: 21–27, DOI: https://doi.org/10.1161/01.cir.102.1.21.Search in Google Scholar PubMed

Biermasz, N.R., van den Oever, N.C., Frolich, M., Arias, A.M., Smit, J.W., Romijn, J.A. and Roelfsema, F. (2003). Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin. Endocrinol. 58: 288–295, DOI: https://doi.org/10.1046/j.1365-2265.2003.01710.x.Search in Google Scholar PubMed

Calabresi, L., Villa, B., Canavesi, M., Sirtori, C.R., James, R.W., Bernini, F. and Franceschini, G. (2004). An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 53: 153–158, DOI: https://doi.org/10.1016/j.metabol.2003.09.007.Search in Google Scholar PubMed

Carmena, R., Duriez, P. and Fruchart, J.C. (2004). Atherogenic lipoprotein particles in atherosclerosis. Circulation 109: Iii2–7, DOI: https://doi.org/10.1161/01.CIR.0000131511.50734.44.Search in Google Scholar PubMed

Chiquette, E., Toth, P.P., Ramirez, G., Cobble, M. and Chilton, R. (2012). Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc. Health Risk Manag. 8: 621–629, DOI: https://doi.org/10.2147/VHRM.S37969.10.2147/VHRM.S37969Search in Google Scholar PubMed PubMed Central

Chiu, S., Williams, P.T. and Krauss, R.M. (2017). Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: a randomized controlled trial. PLoS One 12: e0170664, https://doi.org/10.1371/journal.pone.0170664.Search in Google Scholar PubMed PubMed Central

Chmielewski, M., Heimbürger, O., Stenvinkel, P. and Lindholm, B. (2013). Chapter 4 - Uremic toxicity. In: Nutritional management of renal disease. Academic Press, pp. 49–77.10.1016/B978-0-12-391934-2.00004-7Search in Google Scholar

Chu, N.V., Kong, A.P., Kim, D.D., Armstrong, D., Baxi, S., Deutsch, R., Caulfield, M., Mudaliar, S.R., Reitz, R., Henry, R.R., et al. (2002). Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25: 542–549, DOI: https://doi.org/10.2337/diacare.25.3.542.Search in Google Scholar

Clements, R.S.Jr. and Darnell, B. (1980). Myo-inositol content of common foods: development of a high-myo-inositol diet. Am. J. Clin. Nutr. 33: 1954–1967, DOI: https://doi.org/10.1093/ajcn/33.9.1954.Search in Google Scholar

Damasceno, N.R., Sala-Vila, A., Cofan, M., Perez-Heras, A.M., Fito, M., Ruiz-Gutierrez, V., Martinez-Gonzalez, M.A., Corella, D., Aros, F., Estruch, R., et al. (2013). Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. Atherosclerosis 230: 347–353, DOI: https://doi.org/10.1016/j.atherosclerosis.2013.08.014.Search in Google Scholar

Das, L., Bhaumik, E., Raychaudhuri, U. and Chakraborty, R. (2012). Role of nutraceuticals in human health. J. Food. Sci. Technol. 49: 173–183, DOI: https://doi.org/10.1007/s13197-011-0269-4.10.1007/s13197-011-0269-4Search in Google Scholar

Dejager, S., Bruckert, E. and Chapman, M.J. (1993). Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J. Lipid. Res. 34: 295–308.10.1016/S0022-2275(20)40756-4Search in Google Scholar

Dinu, M., Pagliai, G., Casini, A. and Sofi, F. (2018). Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. Eur. J. Clin. Nutr. 72: 30–43, DOI: https://doi.org/10.1038/ejcn.2017.58.Search in Google Scholar

Dobiasova, M. and Frohlich, J. (2001). The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin. Biochem. 34: 583–588, DOI: https://doi.org/10.1016/s0009-9120(01)00263-6.Search in Google Scholar

Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefebvre, P.J., Murray, G.D., et al. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366: 1279–1289, DOI: https://doi.org/10.1016/S0140-6736(05)67528-9.Search in Google Scholar

Dreon, D.M., Fernstrom, H.A., Campos, H., Blanche, P., Williams, P.T. and Krauss, R.M. (1998). Change in dietary saturated fat intake is correlated with change in mass of large low-density-lipoprotein particles in men. Am. J. Clin. Nutr. 67: 828–836, DOI: https://doi.org/10.1093/ajcn/67.5.828.Search in Google Scholar PubMed

Dreon, D.M., Fernstrom, H.A., Williams, P.T. and Krauss, R.M. (1999). A very low-fat diet is not associated with improved lipoprotein profiles in men with a predominance of large, low-density lipoproteins. Am. J. Clin. Nutr. 69: 411–418, DOI: https://doi.org/10.1093/ajcn/69.3.411.Search in Google Scholar PubMed

Dreon, D.M., Fernstrom, H.A., Williams, P.T. and Krauss, R.M. (2000). Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns. Am. J. Clin. Nutr. 71: 1611–1616, DOI: https://doi.org/10.1093/ajcn/71.6.1611.Search in Google Scholar

Engler, M.M., Engler, M.B., Malloy, M.J., Paul, S.M., Kulkarni, K.R. and Mietus-Snyder, M.L. (2005). Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am. J. Cardiol. 95: 869–871, DOI: https://doi.org/10.1016/j.amjcard.2004.12.014.Search in Google Scholar

Feingold, K.R., Grunfeld, C., Pang, M., Doerrler, W. and Krauss, R.M. (1992). LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12: 1496–1502, DOI: https://doi.org/10.1161/01.atv.12.12.1496.Search in Google Scholar

Ference, B.A., Ginsberg, H.N., Graham, I., Ray, K.K., Packard, C.J., Bruckert, E., Hegele, R.A., Krauss, R.M., Raal, F.J. and Schunkert, H., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the European atherosclerosis society consensus panel. Eur. Heart. J. 38: 2459–2472, DOI: https://doi.org/10.1093/eurheartj/ehx144.Search in Google Scholar

Filippas-Ntekouan, S., Tsimihodimos, V., Filippatos, T., Dimitriou, T. and Elisaf, M. (2018). SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin. Drug. Metab. Toxicol. 14: 1113–1121, DOI: https://doi.org/10.1080/17425255.2018.1541348.Search in Google Scholar

Filippatos, T.D., Gazi, I.F., Liberopoulos, E.N., Athyros, V.G., Elisaf, M.S., Tselepis, A.D. and Kiortsis, D.N. (2007). The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193: 428–437, DOI: https://doi.org/10.1016/j.atherosclerosis.2006.07.010.Search in Google Scholar

Florentin, M., Tselepis, A.D., Elisaf, M.S., Rizos, C.V., Mikhailidis, D.P. and Liberopoulos, E.N. (2010). Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr. Vasc. Pharmacol. 8: 820–830, DOI: https://doi.org/10.2174/157016110793563825.Search in Google Scholar

Florentin, M., Liberopoulos, E.N., Moutzouri, E., Rizos, C.V., Tselepis, A.D. and Elisaf, M.S. (2011). The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr. Med. Res. Opin. 27: 685–692, DOI: https://doi.org/10.1185/03007995.2010.546394.Search in Google Scholar

Freed, M.I., Ratner, R., Marcovina, S.M., Kreider, M.M., Biswas, N., Cohen, B.R. and Brunzell, J.D. (2002). Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol. 90: 947–952, DOI: https://doi.org/10.1016/s0002-9149(02)02659-0.Search in Google Scholar

Fruchart, J.C., Duriez, P. and Staels, B. (1999). Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10: 245–257, DOI: https://doi.org/10.1097/00041433-199906000-00007.Search in Google Scholar PubMed

Fukushima, Y., Hirayama, S., Ueno, T., Dohi, T., Miyazaki, T., Ohmura, H., Mokuno, H., Miyauchi, K., Miida, T. and Daida, H. (2011). Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome. Clin. Chim. Acta. 412: 1423–1427, DOI: https://doi.org/10.1016/j.cca.2011.04.021.Search in Google Scholar

Galletti, F., Fazio, V., Gentile, M., Schillaci, G., Pucci, G., Battista, F., Mercurio, V., Bosso, G., Bonaduce, D., Brambilla, N., et al. (2019). Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. Lipids Health Dis. 18: 66, DOI: https://doi.org/10.1186/s12944-019-1002-y.10.1186/s12944-019-1002-ySearch in Google Scholar

Garoufi, A., Vorre, S., Soldatou, A., Tsentidis, C., Kossiva, L., Drakatos, A., Marmarinos, A. and Gourgiotis, D. (2014). Plant sterols-enriched diet decreases small, dense LDL-cholesterol levels in children with hypercholesterolemia: a prospective study. Ital. J. Pediatr. 40: 42, DOI: https://doi.org/10.1186/1824-7288-40-42.10.1186/1824-7288-40-42Search in Google Scholar

Gentile, M., Calcaterra, I., Strazzullo, A., Pagano, C., Pacioni, D., Speranza, E., Rubba, P. and Marotta, G. (2015). Effects of armolipid plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia. Clin. Lipidol. 10: 475–480, DOI: https://doi.org/10.2217/clp.15.37.10.2217/clp.15.37Search in Google Scholar

Ghazzi, M.N., Perez, J.E., Antonucci, T.K., Driscoll, J.H., Huang, S.M., Faja, B.W. and Whitcomb, R.W. (1997). Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The troglitazone study group. Diabetes 46: 433–439, DOI: https://doi.org/10.2337/diab.46.3.433.Search in Google Scholar

Goldberg, R., Temprosa, M., Otvos, J., Brunzell, J., Marcovina, S., Mather, K., Arakaki, R., Watson, K., Horton, E. and Barrett-Connor, E. (2013). Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program. J. Clin. Endocrinol. Metab. 98: 3989–3998, DOI: https://doi.org/10.1210/jc.2013-1452.Search in Google Scholar

Grundy, S.M. (2002). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421.10.1161/circ.106.25.3143Search in Google Scholar

Guay, V., Lamarche, B., Charest, A., Tremblay, A.J. and Couture, P. (2012). Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. Metabolism 61: 76–83, DOI: https://doi.org/10.1016/j.metabol.2011.06.002.Search in Google Scholar

Guerin, M., Lassel, T.S., Le Goff, W., Farnier, M. and Chapman, M.J. (2000). Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20: 189–197, DOI: https://doi.org/10.1161/01.atv.20.1.189.Search in Google Scholar

Guerin, M., Egger, P., Soudant, C., Le Goff, W., van Tol, A., Dupuis, R. and Chapman, M.J. (2002). Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163: 287–296, DOI: https://doi.org/10.1016/s0021-9150(02)00037-0.Search in Google Scholar

Hadigan, C., Mazza, S., Crum, D. and Grinspoon, S. (2007). Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients. AIDS 21: 2543–2546, DOI: https://doi.org/10.1097/QAD.0b013e3282f25123.10.1097/QAD.0b013e3282f25123Search in Google Scholar

Hanefeld, M. (2009). The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes. Obes. Metab. 11: 742–756, DOI: https://doi.org/10.1111/j.1463-1326.2009.01048.x.Search in Google Scholar

Hasegawa, Y., Hori, M., Nakagami, T., Harada-Shiba, M. and Uchigata, Y. (2018). Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. J. Clin. Lipidol. 12: 62–69.e61, DOI: https://doi.org/10.1016/j.jacl.2017.11.006.Search in Google Scholar

Hayashi, T., Hirano, T., Yamamoto, T., Ito, Y. and Adachi, M. (2006). Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabolism 55: 879–884, DOI: https://doi.org/10.1016/j.metabol.2006.02.014.Search in Google Scholar

Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., Ohara, M., Yamamoto, T., Ito, Y. and Hirano, T. (2017). Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc. Diabetol. 16: 8, DOI: https://doi.org/10.1186/s12933-016-0491-5.Search in Google Scholar

Hirai, H., Higa, M., Morimoto, T., Sakuma, M., Arasaki, O., Nomiyama, T., Node, K., Ueda, S. and Shimabukuro, M. (2019). Dissimilar effects of anagliptin and sitagliptin on lipoprotein subclass in standard or strong statin-treated patients with type-2 diabetes mellitus: a subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density Lipoprotein Cholesterol in Diabetes) trial. J. Clin. Med. 9: 93, DOI: https://doi.org/10.3390/jcm9010093.Search in Google Scholar

Hirano, T., Yoshino, G., Kashiwazaki, K. and Adachi, M. (2001). Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am. J. Hypertens. 14: 908–913, DOI: https://doi.org/10.1016/s0895-7061(01)02141-0.Search in Google Scholar

Hirano, T., Ito, Y., Koba, S., Toyoda, M., Ikejiri, A., Saegusa, H., Yamazaki, J. and Yoshino, G. (2004). Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler. Thromb. Vasc. Biol. 24: 558–563, DOI: https://doi.org/10.1161/01.ATV.0000117179.92263.08.Search in Google Scholar

Hoogeveen, R.C., Gaubatz, J.W., Sun, W., Dodge, R.C., Crosby, J.R., Jiang, J., Couper, D., Virani, S.S., Kathiresan, S., Boerwinkle, E., et al. (2014). Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 34: 1069–1077, DOI: https://doi.org/10.1161/ATVBAHA.114.303284.Search in Google Scholar

Hsueh, W.A. and Law, R.E. (1998). Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am. J. Med. 105: 4s–14s, DOI: https://doi.org/10.1016/s0002-9343(98)00205-8.Search in Google Scholar

Huang, Y., Cheng, Y., Wu, J., Li, Y., Xu, E., Hong, Z., Li, Z., Zhang, W., Ding, M., Gao, X., et al. (2008). Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 7: 494–499, DOI: https://doi.org/10.1016/S1474-4422(08)70094-2.Search in Google Scholar

Hurt-Camejo, E., Camejo, G., Rosengren, B., Lopez, F., Wiklund, O. and Bondjers, G. (1990). Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J. Lipid. Res. 31: 1387–1398.10.1016/S0022-2275(20)42610-0Search in Google Scholar

Inoue, I., Kubota, R., Yanagi, S., Akita, M., Nakano, T., Katayama, S., Shimada, A. and Noda, M. (2017). The new molecular entity evolocumab, one kind of PCSK9 inhibitor, reduce plasma small size LDL-cholesterol levels by using a new standardized method of measuring LDL size. Open. J. Mol. Integr. Physiol. 7: 1, DOI: https://doi.org/10.4236/ojmip.2017.71001.Search in Google Scholar

Ivanova, E.A., Myasoedova, V.A., Melnichenko, A.A., Grechko, A.V. and Orekhov, A.N. (2017). Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid. Med. Cell. Longev. 2017, 1273042, DOI: https://doi.org/10.1155/2017/1273042.10.1155/2017/1273042Search in Google Scholar PubMed PubMed Central

Jebb, S.A., Lovegrove, J.A., Griffin, B.A., Frost, G.S., Moore, C.S., Chatfield, M.D., Bluck, L.J., Williams, C.M. and Sanders, T.A. (2010). Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am. J. Clin. Nutr. 92: 748–758, DOI: https://doi.org/10.3945/ajcn.2009.29096.Search in Google Scholar PubMed PubMed Central

Jenkins, D.J., Wolever, T.M., Rao, A.V., Hegele, R.A., Mitchell, S.J., Ransom, T.P., Boctor, D.L., Spadafora, P.J., Jenkins, A.L., Mehling, C., et al. (1993). Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. N. Engl. J. Med. 329: 21–26, DOI: https://doi.org/10.1056/NEJM199307013290104.Search in Google Scholar PubMed

Jones, J.L., Comperatore, M., Barona, J., Calle, M.C., Andersen, C., McIntosh, M., Najm, W., Lerman, R.H. and Fernandez, M.L. (2012). A Mediterranean-style, low-glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome. Metabolism 61: 366–372, DOI: https://doi.org/10.1016/j.metabol.2011.07.013.Search in Google Scholar PubMed

Jones, P.H., Hunninghake, D.B., Ferdinand, K.C., Stein, E.A., Gold, A., Caplan, R.J. and Blasetto, J.W. (2004). Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther. 26: 1388–1399, DOI: https://doi.org/10.1016/j.clinthera.2004.09.006.Search in Google Scholar PubMed

Jump, D.B., Botolin, D., Wang, Y., Xu, J., Demeure, O. and Christian, B. (2008). Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem. Phys. Lipids 153: 3–13, DOI: https://doi.org/10.1016/j.chemphyslip.2008.02.007.Search in Google Scholar PubMed PubMed Central

Kalogirou, M., Tsimihodimos, V., Gazi, I., Filippatos, T., Saougos, V., Tselepis, A.D., Mikhailidis, D.P. and Elisaf, M. (2007). Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr. Med. Res. Opin. 23: 1169–1176, DOI: https://doi.org/10.1185/030079907x188062.Search in Google Scholar PubMed

Kamijo, Y., Ishii, H., Yamamoto, T., Kobayashi, K., Asano, H., Miake, S., Kanda, E., Urata, H. and Yoshida, M. (2019). Potential impact on lipoprotein subfractions in type 2 diabetes. Clin. Med. Insights. Endocrinol. Diabetes. 12, 1179551419866811, DOI: https://doi.org/10.1177/1179551419866811.10.1177/1179551419866811Search in Google Scholar PubMed PubMed Central

Kawakami, Y., Yamanaka-Okumura, H., Naniwa-Kuroki, Y., Sakuma, M., Taketani, Y. and Takeda, E. (2015). Flaxseed oil intake reduces serum small dense low-density lipoprotein concentrations in Japanese men: a randomized, double blind, crossover study. Nutr. J. 14: 39, DOI: https://doi.org/10.1186/s12937-015-0023-2.Search in Google Scholar PubMed PubMed Central

Kenney, J.J., Barnard, R.J. and Inkeles, S. (1999). Very-low-fat diets do not necessarily promote small, dense LDL particles. Am. J. Clin. Nutr. 70: 423–425, DOI: https://doi.org/10.1093/ajcn/70.3.423.Search in Google Scholar PubMed

Khosravi, M., Hosseini-Fard, R. and Najafi, M. (2018). Circulating low density lipoprotein (LDL). Horm. Mol. Biol. Clin. Invest. 35, 40–52. https://doi.org/10.1515/hmbci-2018-0024.Search in Google Scholar PubMed

Khosravi, M., Poursaleh, A., Ghasempour, G., Farhad, S. and Najafi, M. (2019). The effects of oxidative stress on the development of atherosclerosis. Biol. Chem. 400: 711–732, https://doi.org/10.1515/hsz-2018-0397.Search in Google Scholar PubMed

Kocer, D., Bayram, F. and Diri, H. (2014). The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol. Endocrinol. 30: 367–371, DOI: https://doi.org/10.3109/09513590.2014.887063.Search in Google Scholar PubMed

Kolomvotsou, A.I., Rallidis, L.S., Mountzouris, K.C., Lekakis, J., Koutelidakis, A., Efstathiou, S., Nana-Anastasiou, M. and Zampelas, A. (2013). Adherence to Mediterranean diet and close dietetic supervision increase total dietary antioxidant intake and plasma antioxidant capacity in subjects with abdominal obesity. Eur. J. Nutr. 52: 37–48, DOI: https://doi.org/10.1007/s00394-011-0283-3.Search in Google Scholar PubMed

Krauss, R.M., Wojnooski, K., Orr, J., Geaney, J.C., Pinto, C.A., Liu, Y., Wagner, J.A., Luk, J.M., Johnson-Levonas, A.O., Anderson, M.S., et al. (2012). Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J. Lipid. Res. 53: 540–547, DOI: https://doi.org/10.1194/jlr.M018010.Search in Google Scholar PubMed PubMed Central

Krebs, A., Kratzin, T., Doerfer, J., Winkler, K., Wurm, M., von der Werf-Grohmann, N., Krause, A. and Schwab, K.O. (2016). Decrease of small dense LDL and lipoprotein-associated phospholipase A2 due to human growth hormone treatment in short children with growth hormone deficiency and small for gestational age status. J. Pediatr. Endocrinol. Metab. 29: 203–208, DOI: https://doi.org/10.1515/jpem-2015-0148.Search in Google Scholar PubMed

Krische, D. (2000). The glitazones: proceed with caution. West. J. Med. 173: 54–57, DOI: https://doi.org/10.1136/ewjm.173.1.54.Search in Google Scholar PubMed PubMed Central

Kuriyama, S. (2019). Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials. Clin. Exp. Nephrol. 23: 304–312, DOI: https://doi.org/10.1007/s10157-018-1673-0.Search in Google Scholar PubMed

Kwon, Y.J., Lee, H.S. and Lee, J.W. (2018). Direct bilirubin is associated with low-density lipoprotein subfractions and particle size in overweight and centrally obese women. Nutr. Metab. Cardiovasc. Dis. 28: 1021–1028, DOI: https://doi.org/10.1016/j.numecd.2018.05.013.Search in Google Scholar PubMed

Labonté, E.D., Camarota, L.M., Rojas, J.C., Jandacek, R.J., Gilham, D.E., Davies, J.P., Ioannou, Y.A., Tso, P., Hui, D.Y. and Howles, P.N. (2008). Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am. J. Physiol. Gastrointest. Liver. Physiol. 295: G776–G783, DOI: https://doi.org/10.1152/ajpgi.90275.2008.Search in Google Scholar PubMed PubMed Central

Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G.R., Lupien, P.J. and Despres, J.P. (1997). Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation 95: 69–75, DOI: https://doi.org/10.1161/01.cir.95.1.69.Search in Google Scholar PubMed

Lamarche, B., Desroches, S., Jenkins, D.J., Kendall, C.W., Marchie, A., Faulkner, D., Vidgen, E., Lapsley, K.G., Trautwein, E.A., Parker, T.L., et al. (2004). Combined effects of a dietary portfolio of plant sterols, vegetable protein, viscous fibre and almonds on LDL particle size. Br. J. Nutr. 92: 657–663, DOI: https://doi.org/10.1079/bjn20041241.Search in Google Scholar PubMed

Lamon-Fava, S., Diffenderfer, M.R., Barrett, P.H., Buchsbaum, A., Matthan, N.R., Lichtenstein, A.H., Dolnikowski, G.G., Horvath, K., Asztalos, B.F., Zago, V., et al. (2007). Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid. Res. 48: 1746–1753, DOI: https://doi.org/10.1194/jlr.M700067-JLR200.Search in Google Scholar PubMed

Langreth, R., Keller, M. and Cannon, C. (2016). Decoding big pharma’s secret drug pricing oractices. Bloomberg, New York city.Search in Google Scholar

Lo, J.C., Wang, Y., Tumanov, A.V., Bamji, M., Yao, Z., Reardon, C.A., Getz, G.S. and Fu, Y.X. (2007). Lymphotoxin β receptor-dependent control of lipid homeostasis. Science 316: 285–288, DOI: https://doi.org/10.1126/science.1137221.Search in Google Scholar PubMed

Lopez-Huertas, E. (2012). The effect of EPA and DHA on metabolic syndrome patients: a systematic review of randomised controlled trials. Br. J. Nutr. 107(Suppl. 2): S185–194, DOI: https://doi.org/10.1017/S0007114512001572.Search in Google Scholar PubMed

Lucanic, M., Held, J.M., Vantipalli, M.C., Klang, I.M., Graham, J.B., Gibson, B.W., Lithgow, G.J. and Gill, M.S. (2011). N-acylethanolamine signalling mediates the effect of diet on lifespan in Caenorhabditis elegans. Nature 473: 226–229, DOI: https://doi.org/10.1038/nature10007.10.1038/nature10007Search in Google Scholar PubMed PubMed Central

Maeba, R., Hara, H., Ishikawa, H., Hayashi, S., Yoshimura, N., Kusano, J., Takeoka, Y., Yasuda, D., Okazaki, T., Kinoshita, M., et al. (2008). Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J. Nutr. Sci. Vitaminol. (Tokyo) 54: 196–202, DOI: https://doi.org/10.3177/jnsv.54.196.Search in Google Scholar PubMed

Malakar, A.K., Choudhury, D., Halder, B., Paul, P., Uddin, A. and Chakraborty, S. (2019). A review on coronary artery disease, its risk factors, and therapeutics. J. Cell. Physiol. 234: 16812–16823, DOI: https://doi.org/10.1002/jcp.28350.Search in Google Scholar

Marz, W., Scharnagl, H., Abletshauser, C., Hoffmann, M.M., Berg, A., Keul, J., Wieland, H. and Baumstark, M.W. (2001). Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 103: 1942–1948, DOI: https://doi.org/10.1161/01.cir.103.15.1942.Search in Google Scholar

Mason, R.P., Jacob, R., Corbalan, J.J. and Malinski, T. (2015). Eicosapentaenoic acid reduces small dense low density lipoprotein oxidation and improves endothelial function in vitro as compared to other triglyceride-lowering agents. J. Am. Coll. Cardiol. 65: A2139, DOI: https://doi.org/10.1016/S0735-1097(15)62139-8.Search in Google Scholar

Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B.E., Foley, J.E. and Taskinen, M.R. (2006). Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49: 2049–2057, DOI: https://doi.org/10.1007/s00125-006-0340-2.Search in Google Scholar

Matikainen, N. and Taskinen, M.R. (2013). The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet. Med. 30: 756–757, DOI: https://doi.org/10.1111/dme.12094.Search in Google Scholar

Mauger, J.F., Lichtenstein, A.H., Ausman, L.M., Jalbert, S.M., Jauhiainen, M., Ehnholm, C. and Lamarche, B. (2003). Effect of different forms of dietary hydrogenated fats on LDL particle size. Am. J. Clin. Nutr. 78: 370–375, DOI: https://doi.org/10.1093/ajcn/78.3.370.Search in Google Scholar

McConathy, W.J., Gesquiere, J.C., Bass, H., Tartar, A., Fruchart, J.C. and Wang, C.S. (1992). Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid. Res. 33: 995–1003.10.1016/S0022-2275(20)41415-4Search in Google Scholar

Mizuguchi, K., Yano, T., Tanaka, Y., Ishibashi, M., Masada, A., Mizota, M., Fukutake, K. and Saito, Y. (1993). Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate. Eur. J. Pharmacol. 231: 121–127, DOI: https://doi.org/10.1016/0014-2999(93)90692-b.Search in Google Scholar

Momtazi-Borojeni, A.A., Katsiki, N., Pirro, M., Banach, M., Rasadi, K.A. and Sahebkar, A. (2019). Dietary natural products as emerging lipoprotein(a)-lowering agents. J. Cell. Physiol. 234: 12581–12594, DOI: https://doi.org/10.1002/jcp.28134.Search in Google Scholar PubMed

Mori, Y., Kuriyama, G., Tanaka, T. and Tajima, N. (2009). Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Endocrine 36: 412–418, DOI: https://doi.org/10.1007/s12020-009-9235-6.Search in Google Scholar PubMed

Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N.E., Ahfeldt, T., Sachs, K.V., Li, X., Li, H., Kuperwasser, N., Ruda, V.M., et al. (2010). From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466: 714–719, DOI: https://doi.org/10.1038/nature09266.Search in Google Scholar

Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J.S., Ramakrishnan, R., et al. (2005). Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest. 115: 1323–1332, DOI: https://doi.org/10.1172/JCI23219.Search in Google Scholar

Nakou, E.S., Filippatos, T.D., Georgoula, M., Kiortsis, D.N., Tselepis, A.D., Mikhailidis, D.P. and Elisaf, M.S. (2008). The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr. Med. Res. Opin. 24: 1919–1929, DOI: https://doi.org/10.1185/03007990802177150.Search in Google Scholar

Nauck, M.A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. and Trautmann, M. (2007). A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50: 259–267, DOI: https://doi.org/10.1007/s00125-006-0510-2.Search in Google Scholar

Nishikido, T., Oyama, J., Keida, T., Ohira, H. and Node, K. (2016). High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: the standard versus high-dose therapy with rosuvastatin for lipid lowering (SARD) trial. J. Cardiol. 67: 340–346, DOI: https://doi.org/10.1016/j.jjcc.2015.05.017.Search in Google Scholar

Nordestgaard, B.G. and Zilversmit, D.B. (1989). Comparison of arterial intimal clearances of LDL from diabetic and nondiabetic cholesterol-fed rabbits. Differences in intimal clearance explained by size differences. Arteriosclerosis 9: 176–183, DOI: https://doi.org/10.1161/01.atv.9.2.176.Search in Google Scholar

Nozue, T., Michishita, I., Ito, Y. and Hirano, T. (2008). Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 15: 146–153, DOI: https://doi.org/10.5551/jat.e552.Search in Google Scholar

O’KeefeJr.J.H., Captain, B.K., Jones, P.G. and Harris, W.S. (2004). Atorvastatin reduces remnant lipoproteins and small, dense low‐density lipoproteins regardless of the baseline lipid pattern. Prev. Cardiol. 7: 154–160, DOI: https://doi.org/10.1111/j.1520-037x.2004.03594.x.Search in Google Scholar

Olefsky, J.M. and Saltiel, A.R. (2000). PPAR gamma and the treatment of insulin resistance. Trends Endocrinol. Metab. 11: 362–368, DOI: https://doi.org/10.1016/s1043-2760(00)00306-4.Search in Google Scholar

Ornish, D., Scherwitz, L.W., Billings, J.H., Brown, S.E., Gould, K.L., Merritt, T.A., Sparler, S., Armstrong, W.T., Ports, T.A., Kirkeeide, R.L., et al. (1998). Intensive lifestyle changes for reversal of coronary heart disease. J Am Med Assoc. 280: 2001–2007, DOI: https://doi.org/10.1001/jama.280.23.2001.Search in Google Scholar PubMed

Ose, L., Reyes, R., Johnson-Levonas, A.O., Sapre, A., Tribble, D.L. and Musliner, T. (2007). Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther. 29: 2419–2432, DOI: https://doi.org/10.1016/j.clinthera.2007.10.004.Search in Google Scholar

Packard, C.J. (2003). Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem. Soc. Trans. 31: 1066–1069, DOI: https://doi.org/10.1042/bst0311066.Search in Google Scholar

Pan, M., Cederbaum, A.I., Zhang, Y.L., Ginsberg, H.N., Williams, K.J. and Fisher, E.A. (2004). Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J. Clin. Invest. 113: 1277–1287, DOI: https://doi.org/10.1172/JCI19197.Search in Google Scholar

Patti, A.M., Giglio, R.V., Papanas, N., Rizzo, M. and Rizvi, A.A. (2019). Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev. Clin. Pharmacol. 12: 129–143, DOI: https://doi.org/10.1080/17512433.2019.1567328.Search in Google Scholar

Pedersen, A., Baumstark, M.W., Marckmann, P., Gylling, H. and Sandstrom, B. (2000). An olive oil-rich diet results in higher concentrations of LDL cholesterol and a higher number of LDL subfraction particles than rapeseed oil and sunflower oil diets. J. Lipid Res. 41: 1901–1911.10.1016/S0022-2275(20)32351-8Search in Google Scholar

Peechakara, B.V. and Gupta, M. (2020). Vitamin B3. In: StatPearls. StatPearls Publishing LLC., Treasure Island.Search in Google Scholar

Ranabir, S. and Reetu, K. (2011). Stress and hormones. Indian J. Endocrinol. Metab. 15: 18–22, DOI: https://doi.org/10.4103/2230-8210.77573.10.4103/2230-8210.77573Search in Google Scholar PubMed PubMed Central

Raper, A., Kolansky, D.M. and Cuchel, M. (2012). Treatment of familial hypercholesterolemia: is there a need beyond statin therapy? Curr. Atheroscler. Rep. 14: 11–16, DOI: https://doi.org/10.1007/s11883-011-0215-y.Search in Google Scholar PubMed

Rees, K., Takeda, A., Martin, N., Ellis, L., Wijesekara, D., Vepa, A., Das, A., Hartley, L. and Stranges, S. (2019). Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 3, CD009825, https://doi.org/10.1002/14651858.CD009825.pub3.Search in Google Scholar PubMed PubMed Central

Reiner, Z. (2017). Hypertriglyceridaemia and risk of coronary artery disease. Nat. Rev. Cardiol. 14: 401–411, DOI: https://doi.org/10.1038/nrcardio.2017.31.Search in Google Scholar PubMed

Rizos, E., Tambaki, A.P., Gazi, I., Tselepis, A.D. and Elisaf, M. (2005). Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot. Essent. Fatty Acids 72: 203–209, DOI: https://doi.org/10.1016/j.plefa.2004.10.021.Search in Google Scholar PubMed

Rizzo, M., Pernice, V., Frasheri, A., Di Lorenzo, G., Rini, G.B., Spinas, G.A. and Berneis, K. (2009). Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin. Endocrinol. (Oxf.) 70: 870–875, https://doi.org/10.1111/j.1365-2265.2008.03407.x.Search in Google Scholar PubMed

Rizzo, M., Vekic, J., Koulouris, S., Zeljkovic, A., Jelic-Ivanovic, Z., Spasojevic-Kalimanovska, V., Rini, G.B., Sakellariou, D., Pastromas, S., Mikhailidis, D.P., et al. (2010). Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes. Angiology 61: 584–590, DOI: https://doi.org/10.1177/0003319710366431.Search in Google Scholar PubMed

Roeters van Lennep, H.W., Liem, A.H., Dunselman, P.H., Dallinga-Thie, G.M., Zwinderman, A.H. and Jukema, J.W. (2008). The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr. Med. Res. Opin. 24: 685–694, DOI: https://doi.org/10.1185/030079908X273273.Search in Google Scholar PubMed

Sakamoto, K., Kawamura, M., Kohro, T., Omura, M., Watanabe, T., Ashidate, K., Horiuchi, T., Hara, H., Sekine, N., Chin, R., et al. (2015). Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins. PLoS One 10: e0138332, https://doi.org/10.1371/journal.pone.0138332.Search in Google Scholar PubMed PubMed Central

Sakamoto, K., Kawamura, M., Watanabe, T., Ashidate, K., Kohro, T., Tanaka, A., Mori, Y., Tagami, M., Hirano, T., Yamazaki, T., et al. (2017). Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis. 16: 122, DOI: https://doi.org/10.1186/s12944-017-0508-4.Search in Google Scholar PubMed PubMed Central

Sanchez-Moreno, C., Ordovas, J.M., Smith, C.E., Baraza, J.C., Lee, Y.C. and Garaulet, M. (2011). APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population. J. Nutr. 141: 380–385, DOI: https://doi.org/10.3945/jn.110.130344.Search in Google Scholar PubMed PubMed Central

Satoh, N., Shimatsu, A., Kotani, K., Sakane, N., Yamada, K., Suganami, T., Kuzuya, H. and Ogawa, Y. (2007). Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 30: 144–146, DOI: https://doi.org/10.2337/dc06-1179.Search in Google Scholar PubMed

Scheen, A.J. (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75: 33–59.10.1007/s40265-014-0337-ySearch in Google Scholar PubMed

Schneider, J.G., von Eynatten, M., Parhofer, K.G., Volkmer, J.E., Schiekofer, S., Hamann, A., Nawroth, P.P. and Dugi, K.A. (2004). Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 175: 325–331, DOI: https://doi.org/10.1016/j.atherosclerosis.2004.04.003.Search in Google Scholar PubMed

Sialvera, T.E., Pounis, G.D., Koutelidakis, A.E., Richter, D.J., Yfanti, G., Kapsokefalou, M., Goumas, G., Chiotinis, N., Diamantopoulos, E. and Zampelas, A. (2012). Phytosterols supplementation decreases plasma small and dense LDL levels in metabolic syndrome patients on a westernized type diet. Nutr. Metab. Cardiovasc. Dis. 22: 843–848, DOI: https://doi.org/10.1016/j.numecd.2010.12.004.Search in Google Scholar PubMed

Sjogren, P., Rosell, M., Skoglund-Andersson, C., Zdravkovic, S., Vessby, B., de Faire, U., Hamsten, A., Hellenius, M.L. and Fisher, R.M. (2004). Milk-derived fatty acids are associated with a more favorable LDL particle size distribution in healthy men. J. Nutr. 134: 1729–1735, DOI: https://doi.org/10.1093/jn/134.7.1729.Search in Google Scholar

Sone, H., Takahashi, A., Shimano, H., Ishibashi, S., Yoshino, G., Morisaki, N., Saito, Y., Kawazu, S., Teramoto, T., Fujita, T., et al. (2002). HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. 71: 2403–2412, DOI: https://doi.org/10.1016/s0024-3205(02)02038-6.Search in Google Scholar

Sposito, A.C., Berwanger, O., de Carvalho, L.S.F. and Saraiva, J.F.K. (2018). GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc. Diabetol. 17: 157, DOI: https://doi.org/10.1186/s12933-018-0800-2.Search in Google Scholar

Stampfer, M.J., Krauss, R.M., Ma, J., Blanche, P.J., Holl, L.G., Sacks, F.M. and Hennekens, C.H. (1996). A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. J. Am. Med. Assoc. 276: 882–888.10.1001/jama.1996.03540110036029Search in Google Scholar

Steiner, G. (1996). The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia 39: 1655–1661, DOI: https://doi.org/10.1007/s001250050630.Search in Google Scholar

Steiner, G. (2007). Atherosclerosis in type 2 diabetes: a role for fibrate therapy? Diab. Vasc. Dis. Res. 4: 368–374, DOI: https://doi.org/10.3132/dvdr.2007.067.Search in Google Scholar

Sunayama, S., Watanabe, Y., Ohmura, H., Sawano, M., Shimada, K., Mokuno, H., Daida, H. and Yamaguchi, H. (1999). Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis. 146: 187–193, DOI: https://doi.org/10.1016/s0021-9150(99)00138-0.Search in Google Scholar

Tack, C.J., Smits, P., Demacker, P.N. and Stalenhoef, A.F. (1998). Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21: 796–799, DOI: https://doi.org/10.2337/diacare.21.5.796.Search in Google Scholar PubMed

Takagi, H., Niwa, M., Mizuno, Y., Yamamoto, H., Goto, S.N. and Umemoto, T. (2014). Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart Vessels 29: 287–299, DOI: https://doi.org/10.1007/s00380-013-0358-6.Search in Google Scholar PubMed

Tan, K.C., Pang, R.W., Tiu, S.C. and Lam, K.S. (2003). Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly. Clin. Endocrinol. (Oxf.) 59: 558–564, DOI: https://doi.org/10.1046/j.1365-2265.2003.01849.x.Search in Google Scholar PubMed

Tani, S., Nagao, K. and Hirayama, A. (2013). Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study. Am. J. Cardiovasc. Drugs 13: 443–450, DOI: https://doi.org/10.1007/s40256-013-0043-2.Search in Google Scholar PubMed

Tapan, S., Karadurmus, N., Dogru, T., Ercin, C.N., Tasci, I., Bilgi, C., Kurt, I. and Erbil, M.K. (2011). Decreased small dense LDL levels in Gilbert’s syndrome. Clin. Biochem. 44: 300–303, DOI: https://doi.org/10.1016/j.clinbiochem.2010.12.003.Search in Google Scholar PubMed

Toledo, F.G., Sniderman, A.D. and Kelley, D.E. (2006). Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 29: 1845–1850, DOI: https://doi.org/10.2337/dc06-0455.Search in Google Scholar PubMed

Torimoto, K., Okada, Y., Mori, H., Hajime, M., Tanaka, K., Kurozumi, A., Narisawa, M., Yamamoto, S., Arao, T., Matsuoka, H., et al. (2013). Efficacy of combination of ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 12: 137, DOI: https://doi.org/10.1186/1476-511X-12-137.10.1186/1476-511X-12-137Search in Google Scholar PubMed PubMed Central

Toth, P.P. (2014). Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr. Vasc. Pharmacol. 12: 653–657, DOI: https://doi.org/10.2174/15701611113119990125.Search in Google Scholar PubMed

Toth, P.P., Patti, A.M., Nikolic, D., Giglio, R.V., Castellino, G., Biancucci, T., Geraci, F., David, S., Montalto, G., Rizvi, A., et al. (2015). Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months prospective study. Front. Pharmacol. 6: 299, DOI: https://doi.org/10.3389/fphar.2015.00299.Search in Google Scholar PubMed PubMed Central

Tribble, D.L., Farnier, M., Macdonell, G., Perevozskaya, I., Davies, M.J., Gumbiner, B. and Musliner, T.A. (2008). Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 57: 796–801, DOI: https://doi.org/10.1016/j.metabol.2008.01.026.Search in Google Scholar PubMed

Tuccinardi, D., Farr, O.M., Upadhyay, J., Oussaada, S.M., Klapa, M.I., Candela, M., Rampelli, S., Lehoux, S., Lazaro, I., Sala-Vila, A., et al. (2019). Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: a cross-over, randomized, double-blind, controlled inpatient physiology study. Diabetes Obes. Metab. 21: 2086–2095, DOI: https://doi.org/10.1111/dom.13773.Search in Google Scholar PubMed PubMed Central

Ueda, S., Shimabukuro, M., Arasaki, O., Node, K., Nomiyama, T. and Morimoto, T. (2018). Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk: rationale and study design of the REASON trial. Cardiovasc. Drugs. Ther. 32: 73–80, DOI: https://doi.org/10.1007/s10557-018-6776-z.Search in Google Scholar PubMed PubMed Central

Ueno, H., Koyama, H., Mima, Y., Fukumoto, S., Tanaka, S., Shoji, T., Emoto, M., Shoji, T., Nishizawa, Y. and Inaba, M. (2011). Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. J. Atheroscler. Thromb. 18: 883–890, DOI: https://doi.org/10.5551/jat.9225.Search in Google Scholar PubMed

Urahama, N., Iguchi, G., Shimizu, M., Fujihira, K., Kobayashi, S. and Baba, H. (2008). Smoking and small, dense low-density lipoprotein particles: cross-sectional study. Nicotine Tob. Res. 10: 1391–1395, DOI: https://doi.org/10.1080/14622200802238852.Search in Google Scholar PubMed

Utarwuthipong, T., Komindr, S., Pakpeankitvatana, V., Songchitsomboon, S. and Thongmuang, N. (2009). Small dense low-density lipoprotein concentration and oxidative susceptibility changes after consumption of soybean oil, rice bran oil, palm oil and mixed rice bran/palm oil in hypercholesterolaemic women. J. Int. Med. Res. 37: 96–104, DOI: https://doi.org/10.1177/147323000903700111.Search in Google Scholar PubMed

van Tits, L.J., Smilde, T.J., van Wissen, S., de Graaf, J., Kastelein, J.J. and Stalenhoef, A.F. (2004). Effects of atorvastatin and simvastatin on low-density lipoprotein subtraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J. Investig. Med. 52: 177–184, DOI: https://doi.org/10.1136/jim-52-03-32.Search in Google Scholar PubMed

Varady, K.A., Bhutani, S., Klempel, M.C. and Kroeger, C.M. (2011). Comparison of effects of diet versus exercise weight loss regimens on LDL and HDL particle size in obese adults. Lipids Health Dis. 10: 119, DOI: https://doi.org/10.1186/1476-511X-10-119.10.1186/1476-511X-10-119Search in Google Scholar PubMed PubMed Central

Vecka, M., Dusejovska, M., Stankova, B., Zeman, M., Vavrova, L., Kodydkova, J., Slaby, A. and Zak, A. (2012). N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Neuro. Endocrinol. Lett. 33(Suppl. 2): 87–92.Search in Google Scholar

Verges, B. (2007). Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels. Fundam. Clin. Pharmacol. 21: 15–18, DOI: https://doi.org/10.1111/j.1472-8206.2007.00532.x.Search in Google Scholar PubMed

Vitek, L. (2012). The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front. Pharmacol. 3: 55, DOI: https://doi.org/10.3389/fphar.2012.00055.10.3389/fphar.2012.00055Search in Google Scholar PubMed PubMed Central

Williams, P.T., Bergeron, N., Chiu, S. and Krauss, R.M. (2019). A randomized, controlled trial on the effects of almonds on lipoprotein response to a higher carbohydrate, lower fat diet in men and women with abdominal adiposity. Lipids Health Dis. 18: 83, DOI: https://doi.org/10.1186/s12944-019-1025-4.Search in Google Scholar PubMed PubMed Central

Winkler, K., Jacob, S., Muller-Schewe, T., Hoffmann, M.M. and Konrad, T. (2012). Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 220: 189–193, DOI: https://doi.org/10.1016/j.atherosclerosis.2011.10.043.Search in Google Scholar PubMed

Wolak, T., Toledano, R., Novack, V., Sharon, A., Shalev, A. and Wolak, A. (2014). Doxazosin to treat hypertension: it’s time to take it personally--a retrospective analysis of 19, 495 patients. J. Hypertens. 32: 1132–1137; discussion 1137, DOI: https://doi.org/10.1097/HJH.0000000000000119.Search in Google Scholar PubMed

Yamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H. and Ishibashi, S. (2019). Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα): pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination. Int. J. Mol. Sci. 20, 480–27. https://doi.org/10.3390/ijms20225537.Search in Google Scholar PubMed PubMed Central

Yoshino, G., Hirano, T. and Kazumi, T. (2002). Treatment of small dense LDL. J. Atheroscler. Thromb. 9: 266–275, DOI: https://doi.org/10.5551/jat.9.266.Search in Google Scholar PubMed

Younis, N., Charlton-Menys, V., Sharma, R., Soran, H. and Durrington, P.N. (2009). Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 202: 162–168, DOI: https://doi.org/10.1016/j.atherosclerosis.2008.04.036.Search in Google Scholar PubMed

Yu, D., Murdoch, S.J., Parikh, S.J., Marcovina, S.M., Cobitz, A., Chen, H. and Brunzell, J.D. (2006). Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diab. Vasc. Dis. Res. 3: 189–196, DOI: https://doi.org/10.3132/dvdr.2006.029.Search in Google Scholar PubMed

Yunoki, K., Nakamura, K., Miyoshi, T., Enko, K., Kubo, M., Murakami, M., Hata, Y., Kohno, K., Morita, H., Kusano, K.F., et al. (2011). Impact of hypertriglyceridemia on endothelial dysfunction during statin +/- ezetimibe therapy in patients with coronary heart disease. Am. J. Cardiol. 108: 333–339, DOI: https://doi.org/10.1016/j.amjcard.2011.03.049.Search in Google Scholar PubMed

Zahr, R. and Fleseriu, M. (2018). Updates in diagnosis and treatment of acromegaly. Eur. Endocrinol. 14: 57–61, DOI: https://doi.org/10.17925/EE.2018.14.2.57.Search in Google Scholar PubMed PubMed Central

Zampelas, A. (2013). Nuts and not olive oil decrease small and dense LDL: results from the PREDIMED study. Atherosclerosis 231: 59–60, DOI: https://doi.org/10.1016/j.atherosclerosis.2013.07.058.Search in Google Scholar PubMed

Zhang, Y., Xu, R.X., Li, S., Zhu, C.G., Guo, Y.L., Sun, J. and Li, J.J. (2015). Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 25: 426–433, DOI: https://doi.org/10.1016/j.numecd.2015.01.006.Search in Google Scholar PubMed